They can look at your age, cycle pattern, and health history to help determine the next best steps for you
Announces Extension of Investor Relations Agreement with Emerging Markets Consulting, LLC June 5, 2026 The Precision Peptide Company Inc
Administration and Safety TB-500 Administration: Commonly given via subcutaneous injection Typically used in 46 week cycles Initial phase: 23 injections per week Maintenance phase: Reduced frequency as directed by a healthcare provider BPC-157 Administration: Can be taken via subcutaneous injection, localized injection, or oral capsule (for gut health) Dosage varies depending on injury type and severity Can be used for short-term injury recovery or longer cycles for chronic conditions Safety Note: Both TB-500 and BPC-157 should be used under medical supervision
About the study The phase 3a, multicenter, randomized, double-blind, placebo- and active-controlled REDEFINE 1 trial enrolled 3,417 adults across 22 countries
Key differences between cagrilintide and semaglutide Mechanism: Cagrilintide: Amylin receptor agonist Semaglutide: GLP-1 receptor agonist Different pathways, complementary effects Gastric emptying: Cagrilintide: Very strong effect (dramatic slowing) Semaglutide: Moderate effect Combined: Maximum slowing Appetite suppression: Cagrilintide: Works via amylin/calcitonin receptors Semaglutide: Works via GLP-1 receptors in brain Combined: Dual-pathway suppression Side effects: Cagrilintide: More nausea/GI effects (stronger gastric slowing) Semaglutide: Moderate GI effects Combined: Higher side effect risk but manageable Approval status: Cagrilintide: Investigational (not approved) Semaglutide: FDA approved CagriSema combination: Phase 3 trials Weight loss monotherapy: Cagrilintide alone: 10-12% body weight loss Semaglutide alone: 10-15% body weight loss Combined: 15-25% body weight loss Why combining cagrilintide and semaglutide works synergistically The combination targets weight loss through multiple pathways
